Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003721 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00003721 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 33 participants.
The verdict
NCT00003721, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of COL-3 in treating patients who have advanced solid tumors.
Interventions
- DRUG incyclinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 1998-11 |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003721
The ClinicalTrials.gov registry entry for NCT00003721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which incyclinide is the first listed.
NCT00003721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003721 about?
NCT00003721 is a clinical study titled "Chemotherapy in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of COL-3 in treating patients who have advanced solid tumors.
What is the current status of trial NCT00003721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 1998-11. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00003721?
The interventions under investigation include: incyclinide (DRUG).
Who is sponsoring clinical trial NCT00003721?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.